Eli Lilly launches program to help boost employer coverage of obesity drugs in U.S.

Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity treatment benefits and costs.

Pfizer secures China nod for obesity drug as generics loom

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more crowded with the looming entry of generics.

Canada is a global leader in obesity care guidelines, so why are Canadians still waiting months for treatment at home?

Canada is recognized globally for its world-leading obesity care guidelines — yet Canadians continue to struggle to access the very treatment plans we’ve developed. Meanwhile, the same model of care ...

Novo Nordisk stock tumbles as next-gen obesity shot underperforms Lilly’s tirzepatide

Patients taking a standard dose of CagriSema lost 20.2% of their body weight after 84 weeks, compared with 23.6% for Lilly’s tirzepatide. “The trial did not achieve its primary endpoint of ...